__timestamp | Amgen Inc. | Viking Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 4699000000 | 1244910 |
Thursday, January 1, 2015 | 4846000000 | 5029636 |
Friday, January 1, 2016 | 5062000000 | 4846776 |
Sunday, January 1, 2017 | 4870000000 | 5329003 |
Monday, January 1, 2018 | 5332000000 | 7121000 |
Tuesday, January 1, 2019 | 5150000000 | 9128000 |
Wednesday, January 1, 2020 | 5730000000 | 10731000 |
Friday, January 1, 2021 | 5368000000 | 10701000 |
Saturday, January 1, 2022 | 5414000000 | 16121000 |
Sunday, January 1, 2023 | 6179000000 | 37021000 |
Monday, January 1, 2024 | 7096000000 |
In pursuit of knowledge
In the competitive world of biotechnology, understanding the financial dynamics of industry leaders is crucial. Amgen Inc., a titan in the field, has consistently demonstrated robust financial health, particularly in its Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise over the decade.
In stark contrast, Viking Therapeutics, Inc., a smaller player, has seen its SG&A expenses grow from a modest $1.2 million in 2014 to $37 million in 2023. This represents a staggering increase of over 2,800%, reflecting its aggressive expansion and investment in growth.
This comparison highlights the differing strategies of established giants and emerging innovators in the biotech sector, offering valuable insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Amgen Inc.
AbbVie Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Amgen Inc. and Vertex Pharmaceuticals Incorporated
Comparing SG&A Expenses: Amgen Inc. vs Insmed Incorporated Trends and Insights
Amgen Inc. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amgen Inc. and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
Amgen Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Amgen Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.